- Home
- AYI vs MDGL Comparison
AYI vs MDGL Comparison
Compare AYI & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AYI | MDGL |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 12.1B |
| IPO Year | 2001 | 2005 |
Fundamental Metrics
Financial Performance| Metric | AYI | MDGL |
|---|---|---|
| Price | $291.81 | $515.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $369.17 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 337.1K | 256.2K |
| Earning Date | 04-02-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ 6.91 | N/A |
| Revenue | ★ $3,461,000,000.00 | $180,133,000.00 |
| Revenue This Year | $7.51 | $58.39 |
| Revenue Next Year | $5.14 | $48.55 |
| P/E Ratio | $42.47 | ★ N/A |
| Revenue Growth | ★ 4.05 | N/A |
| 52 Week Low | $253.03 | $265.00 |
| 52 Week High | $380.17 | $615.00 |
Technical Indicators
Market Signals| Indicator | AYI | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 53.94 | 49.29 |
| Support Level | $282.93 | $502.45 |
| Resistance Level | $301.51 | $539.17 |
| Average True Range (ATR) | 7.02 | 20.53 |
| MACD | 0.41 | -1.85 |
| Stochastic Oscillator | 46.78 | 24.98 |
Price Performance
Historical ComparisonAbout AYI Acuity Brands Inc.
Acuity is a leading industrial technology company that offers lighting, lighting controls, and intelligent building solutions. It designs, manufactures, and brings to market products and services relating to these and other offerings. Acuity has two reportable segments: Acuity Brands Lighting and Acuity Intelligent Spaces. ABL sells commercial, architectural, and specialty lighting, including components and control systems. AIS offers building management and audio/visual solutions to help make buildings intelligent.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.